Cargando…
High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment
Docetaxel-induced fluid retention (DIFR) cumulatively occurs and is one of the most troublesome adverse effects. This study aimed to determine whether high dose dexamethasone (DEX) could prevent DIFR during breast cancer treatment. Breast cancer patients receiving docetaxel (75 mg/m(2))-containing r...
Autores principales: | Saito, Yoshitaka, Kanno, Ryota, Takekuma, Yoh, Takeshita, Takashi, Oshino, Tomohiro, Sugawara, Mitsuru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247720/ https://www.ncbi.nlm.nih.gov/pubmed/37286589 http://dx.doi.org/10.1038/s41598-023-36264-4 |
Ejemplares similares
-
Impact of systemic dexamethasone dosage on docetaxel-induced oral mucositis in patients with breast cancer
por: Saito, Yoshitaka, et al.
Publicado: (2023) -
Impact of systemic dexamethasone administration on oral mucositis induced by anthracycline-containing regimens in breast cancer treatment
por: Saito, Yoshitaka, et al.
Publicado: (2022) -
Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report
por: Saito, Yoshitaka, et al.
Publicado: (2022) -
Impact of reducing day 1 dexamethasone dose in anthracycline-containing regimens on acute gastrointestinal symptoms associated with breast cancer treatment
por: Saito, Yoshitaka, et al.
Publicado: (2021) -
Severe Hypertriglyceridemia Induced by Docetaxel: A Novel Case Report
por: Saito, Yoshitaka, et al.
Publicado: (2021)